BrightGene
China - SuzhouBiotechnology
Focus: BrightGene is a Suzhou-based biotech founded in 2022 specializing in APIs and small-molecule therapeutics, currently focused on infectious diseases with an expanding pipeline in metabolic disease.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Open Jobs
0
About BrightGene
AI assessmentNot HiringNo open roles listed right now. Follow BrightGene to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from BrightGene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Post-LOE
Post-loss-of-exclusivity ANDA product; limited revenue contribution and declining relevance as generic commodity.
Help build intelligence for BrightGene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.